QureTech Bio AB has received a European patent for GmPcides, a new class of synthetic antibacterials effective against drug-resistant bacteria like MRSA. This patent guarantees protection until 2041.
QureTech Bio has secured a SEK 14 million investment from Kempestiftelserna and Nascent Invest to enhance its development of innovative antibiotics targeting antimicrobial resistance. The funding will accelerate programs addressing multidrug-resistant bacteria, significantly impacting global health advancements.
Umeå based QureTech Bio has appointed Markus Thor as CEO, succeeding Helén Fält. With 30 years of pharmaceutical experience, Thor aims to advance the life science company's pipeline toward clinical trials, focusing on solutions for antimicrobial resistance.
QureTech Bio AB (QTB), a pharmaceutical development company originating from Umeå University, proudly announces the appointment of three new board members at its Annual General Meeting held on May 25, 2023. This strategic move is aimed at further enhancing QTB's drug and business development.
The newly appointed board members are:
Yijing Sun Hultgren
Yijing has over a decade of experience
Umeå-based QureTech Bio AB receives support from the Swedish Research Council's major investment ENABLE-2, which in collaboration with Vinnova gives small and medium-sized companies access to the ENABLE-2 platform to continue development of new antibiotics.
Umeå-based pharmaceutical development company QureTech Bio is hiring more people as it intensifies its work to combat antibiotic resistance. “We recently received a major investment which has created long-term security in the company. With more people in place, we can now really push on and look to the future”, says Helén Fält, who was recently appointed the new CEO of QureTech Bio.
Umeå-based biotech company QureTech Bio has appointed Helén Fält as its new acting CEO, replacing Fredrik Almqvist, one of the company’s original founders. “We have recently secured significant new investment and so it feels like the perfect time for Helén to come in and develop our business even further,” says Fredrik Almqvist.